Market Size of Thyroid Gland Disorders Treatment Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 3.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Thyroid Gland Disorders Treatment Market Analysis
The thyroid gland disorders treatment market is projected to register a CAGR of 3.5% during the forecast period.
COVID-19 had an adverse impact on people with thyroid gland disorders. For instance, according to an article published in the Journal of the International Medicine and Research in February 2022, SARS-CoV-2 has specific targets in the thyroid and the entire hypothalamic-pituitary-thyroid (HPT) axis. Most thyroid illnesses, such as Graves' disease, euthyroid sick syndrome, Hashimoto's thyroiditis, and subacute thyroiditis, were identified as COVID-19 sequelae, and each of these disorders' etiologies was linked to the SARS-CoV-2 virus. Also, as per an article published in October 2022 in the Diabetes & Metabolic Syndrome, thyroid abnormalities increased the risk of COVID-19 composite poor outcomes and were influenced by the patient's age. Therefore, this has increased thyroid treatment during the pandemic. The market is expected to register a stable growth rate during the forecast period.
The market for thyroid gland disorders treatment is primarily driven by the increasing burden of the patient population with iodine deficiency. As per an article published by the Ministry of Health and Family Welfare in February 2022, the prevalence of self-reported goiter or thyroid disorders increased to 2.9% last year in India. Thus, the increasing number of thyroid disorders is expected to boost market growth.
As per an article published in the National Center of Biotechnology Information in August 2022, iodine was one of the most common nutrient deficiencies and was estimated to have affected 35-45% of the world's population last year. Iodine deficiency is the most common cause of goiter, affecting 2.2 billion people worldwide. Thus, the high burden of iodine deficiency is expected to lead to thyroid disorders which in turn is expected to accelerate the market growth.
The rising approvals, launches, and partnerships by market players are also expected to propel market growth. For instance, in November 2021, Swiss medtech company Bloom Diagnostics launched its Bloom Thyroid Test to help detect hypothyroidism. Bloom has developed a smart self-testing system for a range of medical conditions. The Bloom Thyroid test received the approval certificate from the Notified Body, which will allow users to perform the test at home.
Therefore, owing to the factors such as the high burden of thyroid and rising product approvals and launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatments and availability of alternative treatments are estimated to restrain the market growth during the forecast period.
Thyroid Gland Disorders Treatment Industry Segmentation
As per the scope of the report, thyroid gland disorder is a condition when the thyroid gland produces either too much or too little thyroid hormones.
The Thyroid Gland Disorders Treatment Market is Segmented by Type of Disorder (Hypothyroidism, Hyperthyroidism, and Other Types of Disorder), Route of Administration (Oral, Parenteral, and Other Routes of Administration), Drug Class (Thioamides, Ionic Inhibitors, Hormone-release Inhibitors, and Other Drug Classes), Distribution Channel (Wholesale Distribution, Retail Stores, and Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
By Type of Disorder | |
Hypothyroidism | |
Hyperthyroidism | |
Other Types of Disorder |
By Route of Administration | |
Oral | |
Parenteral | |
Other Routes of Administration |
By Drug Class | |
Thioamides | |
Ionic Inhibitors | |
Hormone-release Inhibitors | |
Other Drug Classes |
By Distribution Channel | |
Wholesale Distribution | |
Retail Stores | |
Online Pharmacy |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Thyroid Gland Disorders Treatment Market Size Summary
The thyroid gland disorders treatment market is anticipated to experience steady growth over the forecast period, driven by the increasing prevalence of thyroid disorders linked to iodine deficiency and the impact of COVID-19 on thyroid health. The pandemic has exacerbated thyroid conditions, leading to a rise in demand for treatments. The market is further propelled by the introduction of innovative products and partnerships among key players, such as the launch of home-testing solutions for hypothyroidism. Despite the high cost of treatments and the availability of alternative therapies posing challenges, the market is expected to expand due to the growing burden of thyroid disorders and the ongoing advancements in treatment options.
Regionally, North America is projected to lead the market, supported by a high incidence of thyroid diseases and a concentration of market players. The region benefits from increased awareness and early detection initiatives, which are expected to drive market growth. The approval of new therapies and products, such as those for differentiated thyroid cancer, further bolsters the market. The competitive landscape is dominated by major global players, with potential for new entrants due to ongoing innovations in therapeutics. Overall, the market's growth is underpinned by the rising incidence of thyroid disorders and the continuous development of effective treatment solutions.
Thyroid Gland Disorders Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Patient Population with Iodine Deficiency
-
1.2.2 Rising Government Initiatives for Thyroid Gland Screening and Treatment
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Treatments
-
1.3.2 Availability of Alternative Treatment
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Type of Disorder
-
2.1.1 Hypothyroidism
-
2.1.2 Hyperthyroidism
-
2.1.3 Other Types of Disorder
-
-
2.2 By Route of Administration
-
2.2.1 Oral
-
2.2.2 Parenteral
-
2.2.3 Other Routes of Administration
-
-
2.3 By Drug Class
-
2.3.1 Thioamides
-
2.3.2 Ionic Inhibitors
-
2.3.3 Hormone-release Inhibitors
-
2.3.4 Other Drug Classes
-
-
2.4 By Distribution Channel
-
2.4.1 Wholesale Distribution
-
2.4.2 Retail Stores
-
2.4.3 Online Pharmacy
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Thyroid Gland Disorders Treatment Market Size FAQs
What is the current Thyroid Gland Disorders Treatment Market size?
The Thyroid Gland Disorders Treatment Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Thyroid Gland Disorders Treatment Market?
Abbvie Inc., Merck KGaA, Pfizer Inc., Exelixis Inc. and Viatris Inc. are the major companies operating in the Thyroid Gland Disorders Treatment Market.